Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04381494 · ClinicalTrials.gov registry record · Phase 4
Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.
A Phase 4 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT04381494 is a Phase 4 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 40 participants.
The verdict
NCT04381494, a Phase 4 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
A study of whether mobile devices can improve the detection of pulmonary AEs (including pneumonitis) in stage III NSCLC patients post-CRT, while on durvalumab.
Interventions
- DEVICE Multiparametric Mobile Technology
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-04-27 |
| Est. Completion | 2022-01-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04381494
The ClinicalTrials.gov registry entry for NCT04381494 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Multiparametric Mobile Technology is the first listed.
NCT04381494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04381494 about?
NCT04381494 is a clinical study titled "Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.". A study of whether mobile devices can improve the detection of pulmonary AEs (including pneumonitis) in stage III NSCLC patients post-CRT, while on durvalumab.
What is the current status of trial NCT04381494?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2020-04-27. Estimated completion is 2022-01-27.
What interventions are being tested in trial NCT04381494?
The interventions under investigation include: Multiparametric Mobile Technology (DEVICE).
Who is sponsoring clinical trial NCT04381494?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.